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Aim To evaluate the clinical utility of incorporating a nov-
el heavy/light chain immunoassay (HLC) into the existing 
methods for the assessment of multiple myeloma (MM) 
patients.
Methods Convenience sera samples from 90 previously 
treated IgG and IgA MM patients in different disease stages 
were analyzed. The study was conducted in Clinical Hospi-
tal Center Zagreb between 2011 and 2013. The collected 
sera were analyzed by standard laboratory techniques (se-
rum protein electrophoresis, quantification of total immu-
noglobulins, serum immunofixation, serum free light chain 
[FLC] assay) and HLC assay.
Results HLC ratios outside the normal range were found 
in 58 of 90 patients, including 28 out of 61 patients with 
total immunoglobulin measurements within the normal 
range and 5 out of 23 patients in complete response. Both 
elevated HLC isotype level and abnormal HLC ratio cor-
related with the parameters of tumor burden, including 
percentage of plasma cells in the bone marrow (P < 0.001 
and P = 0.002, respectively) and an abnormal serum FLC ra-
tio (for both P < 0.001). In addition, abnormal HLC isotype 
level correlated with serum beta-2-microglobulin level 
(P = 0.038). In terms of prognosis, abnormal HLC isotype 
level and abnormal HLC ratio were significantly associ-
ated with shorter overall survival (P < 0.001 and P = 0.002, 
respectively). Interestingly, suppression of the uninvolved 
(polyclonal) isotype pair, but not other non-myeloma im-
munoglobulin isotypes, was also associated with a short-
er overall survival (P = 0.021). In a multivariate analysis, an 
abnormal HLC ratio and β2-microglobulin level >3.5mg/L 
were independent risk factors for survival.
Conclusion The new HLC assay has greater sensitivity in 
detecting monoclonal protein, correlates with tumor bur-
den markers, and affects patients’ outcome.
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Hematological malignancy multiple myeloma is charac-
terized by the proliferation of monoclonal plasma cells in 
the bone marrow, which usually leads to the secretion of 
monoclonal intact immunoglobulins (Ig), free light chains 
(FLC), or both, into the serum. Consequently, the measure-
ment of monoclonal proteins is integral to diagnosing 
multiple myeloma, monitoring of response to treatment, 
and detecting relapse (1-3). Conventional methods rely 
principally on serum electrophoresis together with either 
urine electrophoresis for the detection of FLC M-proteins 
or nephelometric quantification of total Igs for intact Ig 
paraprotein measurement. However, these standard tech-
niques often do not have the required sensitivity or do not 
correlate with the patient’s clinical status (4-7).
The ability to detect monoclonal serum FLC has been sub-
stantially increased by the introduction of the serum FLC 
assay, improving the diagnosis, monitoring, and prognosis 
of a number of plasma cell dyscrasias (8,9). Still, a number 
of problems associated with the detection of monoclonal 
intact Igs persist. Serum Ig concentrations can change for 
≥50% with fluctuations in blood volume and/or hemat-
ocrit (10). In the case of monoclonal IgGs, the serum con-
centration can be also influenced by altered metabolism 
due to recycling of IgG by the neonatal Fc receptors (11-
13). Furthermore, monoclonal proteins, in particular IgA 
paraproteins, may not be accurately quantified by serum 
protein electrophoresis (SPE) due to co-migration with 
other serum proteins (14,15). Finally, one of the major limi-
tations of measuring total Igs is the inability to distinguish 
between the monoclonal component and polyclonal Ig 
background.
These problems can be addressed by a recently developed 
heavy/light chain (HLC) immunoassay. Using specific an-
tibodies targeted to junctional epitopes of the heavy and 
light chains of Ig molecules, HLC immunoassay separately 
quantifies different light chain types of each Ig class (IgGκ, 
IgGλ, IgAκ, IgAλ, etc), thus providing accurate quantifica-
tion of both the involved and uninvolved components of 
the patient’s affected Ig isotype. The ratio of the mono-
clonal and polyclonal Igs of the same isotype (IgGκ/IgGλ, 
IgAκ/IgAλ) provides a sensitive measure of monoclonality, 
while minimizing the influence of changes in blood vol-
ume/hematocrit and the effect of IgG recycling (16,17).
Previous studies using this novel assay in specific, con-
trolled patient cohorts found the HLC ratio to be useful 
for screening, monitoring, and risk stratification of pa-
tients with multiple myeloma, but also with other 
monoclonal gammopathies, such as monoclonal gammo-
pathy of undetermined significance (MGUS) and amyloid 
light-chain (AL) amyloidosis (18-20). The aim of this study 
was to evaluate the ability of the new assay – HLC isotype 
measurements – to detect monoclonal protein (ie, residual 
disease) in previously treated multiple myeloma patients 
and to determine whether these patients can benefit from 
adding the new assay into a routine assessment.
PatIeNtS aND MethoDS
The study included 90 unselected intact Ig multiple my-
eloma patients in different clinical stages (symptomatic 
disease) who had received at least one line of different 
treatment regiments (the number of patients was limited 
by availability of serum assays but also by the number of 
patients who were willing to enter the study). Written in-
formed consent was obtained from each patient before 
entering the study. Patients were enrolled consecutively 
as they presented for routine assessment at our hospital 
between January 2011 and October 2013. At the time of 
the assessment, all patients already completed treatment 
regiments. The median follow-up period was 17.4 months 
(range 0.5-46.1 months; follow up period is defined as time 
elapsed from the day of the sampling until January 2015 
when statistical analysis was performed). Median age was 
61 years (range 39-84). A complete clinical and laboratory 
assessment was performed on convenience samples using 
standard laboratory techniques (SPE, nephelometric quan-
tification of total immunoglobulins, serum immunofixation 
[IFE], and serum FLC assay) in addition to the novel HLC as-
say, complete blood count, and bone marrow analysis. Bio-
chemical parameters – serum albumin, β
2-microglobulin, 
serum creatinine, serum calcium levels, and lactate dehy-
drogenase were also measured. This study was approved 
by the Ethics Committee of the University Hospital Center 
Zagreb and Ethics Committee of the Medical School, Uni-
versity of Zagreb.
Serum HLC and FLC levels were measured using the poly-
clonal antisera assays Hevylite® and Freelite®, respectively 
(The Binding Site, Birmingham, UK) and performed on a 
Dade Behring BNII analyzer (Siemens AG, Munich, Ger-
many) according to the manufacturer’s instructions. Nor-
mal ranges for HLC isotypes and their ratios were obtained 
from the manufacturer’s instructions. SPE and sIFE were 
performed on a Hydrasys platform (Sebia, Paris, France). 
Total Igs were measured using Tina-quant Gen.2 reagents 
(Roche, Rotkreuz, Switzerland) on a Cobas® 6000 platform 
(Roche) according to the manufacturer’s instructions.
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The data were analyzed using the R package (21). Sub-
groups of patients were compared using the Mann-Whit-
ney test for continuous variables and the χ2 for categori-
cal variables. Overall survival (OS) was estimated with 
the Kaplan-Meier method and the subgroups of patients 
were compared using the log-rank test. The association 
of time to death with relevant variables was evaluated in 
a multivariate analysis with the use of Cox’s proportional-
hazard regression model. P values ≤0.05 were considered 
significant.
ReSuLtS
A total of 66/90 (73%) patients had IgG myeloma (47 IgGκ 
and 19 IgGλ) and 24/90 (27%) had IgA myeloma (13 IgAκ 
and 11 IgAλ). According to international response crite-
ria (22), at the moment of the study 67/90 patients had 
achieved a partial response or better (10 partial responses, 
34 very good partial responses, and 23 complete respons-
es), 1 patient showed minimal response, 10 patients had 
stable disease, 7 patients had progressive disease, and 5 
patients were at relapse (Table 1).
the ability of the new assay to detect monoclonal 
immunoglobulin
One of the aims of our study was to determine the ability 
of HLC isotype measurement to detect monoclonal pro-
tein and to compare it with the standard test for Ig mea-
surement. Standard test showed abnormal (elevated) total 
Ig measurement in 29/90 (32%) patients and Ig measure-
ment within the normal range in 61/90 (68%) of patients. 
All patients with abnormal total Ig values according to 
standard test also had abnormal Ig values according to 
the new assay (abnormal involved HLC isotype value and/
or abnormal HLC ratio). However, 28 (46%) of the 61 pa-
tients with normal Ig values according to the standard test 
(28/90 of total, 31%) had an abnormal HLC ratio, signifying 
the presence of monoclonal protein.
Relationship between hLC ratio and serum FLC ratio
Abnormal HLC ratio in the presence of normal FLC ratio 
revealed monoclonal protein in additional 4/23 (17%) pa-
tients in complete response, 8/34 (24%) patients with very 
good partial response, and 3/10 (30%) patients with stable 
disease (Table 2). In all patients with progressive disease, 
both assays were positive. HLC and FLC assays provided 
sometimes differing but complementary information, ie, 
in some patients both assays indicated the presence of 
monoclonal protein and in others only one of the assays 
did so. This was perhaps most notable in 8/23 patients 
who had achieved complete response (Table 2). Never-
theless, 2 of the 5 patients in complete response but with 
an abnormal HLC ratio suffered a relapse during the fol-
low up period.
taBLe 1. Study population characteristics at re-evaluation. Values are shown as medians and range
all IgG patients Iga patients
Number of patients  90  66  24
Age (years)  61 (39-84)  61 (39-84)  64 (45-84)
Sex (male/female)  42/48  32/34  10/14
Total immunoglobulin – standard method (g/L)  10.48 (1.05-54.32)  11.48 (2.85-54.32)   4.76 (1.05-35.49)
Serum free light chain ratio   1.08 (0.0-299.0)   1.16 (0.0-299.0)   0.75 (0-25.8)
β-2-microglobulin (mg/L)   2.34 (1.3-11.15)   2.3 (1.3-11.15)   2.45 (1.70-9.78)
Albumin (g/L)  41.8 (16.8-69.0)  42.15 (30.6-69.0)  39.2 (16.8-44.9)
Hemoglobin (g/L) 125 (86-179) 125 (86-149) 125 (101-179)
Thrombocytes ( × 109/L) 187 (43-567) 190 (43-567) 184 (99-378)
Creatinine (µmol/L)  90 (47-256)  90 (47-172)  77 (51-256)
Serum calcium (mmol/L)   2.34 (1.82-2.86)   2.33 (1.97-2.79)   2.43 (1.82-2.86)
Lactate dehydrogenase (U/L) 182 (79-862) 190 (79-862) 158 (113-264)
Percentage of plasma cells   6 (0-95)   6 (0-70)   7.5 (0-95)
International Staging System stage I / II / III (No.)  53 / 34 / 3  36 / 29 / 1  17 / 5/ 2
Complete response (No.)  23  15  8
Very good partial response (No.)  34  28  6
Partial response (No.)  10   8  2
MR/SD/PD/relapse (No.)   1 /10 / 7 / 5   1 / 5 / 4 / 5  0 / 5 / 3 / 0
*MR – minimal response; SD – stable disease; PD – progressive disease.
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Disease variables and involved (monoclonal) hLC 
measurements
In order to assess whether the new assay truly reflected dis-
ease activity and provided good measurement of tumor 
burden (ie, residual disease), we tested the correlations be-
tween HLC measurements (involved HLC isotype values and 
HLC ratio) and other disease variables. Looking at the entire 
cohort, abnormal HLC ratio values correlated with the per-
centage of clonal plasma cells in the bone marrow (P = 0.002) 
and an abnormal serum FLC ratio (P < 0.001). Involved HLC 
isotype concentration above normal values correlated with 
serum beta-2-microglobulin values (P = 0.038), percentage 
of clonal plasma cells in the bone marrow (P < 0.001), and 
abnormal serum FLC ratio (P < 0.001).
Analyzing the data according to Ig isotype, abnormal IgGκ/
IgGλ HLC ratios (normal range 0.98-2.75) correlated with 
the percentage of clonal plasma cells in the bone mar-
row (P = 0.020), abnormal serum FLC ratio (P < 0.001), and 
hemoglobin concentration (P = 0.032). Monoclonal IgGκ 
or IgGλ isotype concentrations above the normal upper 
limit (for IgGκ above 9.78 g/L and for IgGλ above 5.71 g/L) 
correlated with serum beta-2-microglobulin concentra-
tion (P = 0.011), percentage of clonal plasma cells in the 
bone marrow (P = 0.007), and abnormal serum FLC ratio 
(P = 0.002).
Abnormal IgAκ/IgAλ ratios (normal range 0.80-2.04) corre-
lated with abnormal serum FLC ratio (normal range 0.26-
1.65; P = 0.023) and serum beta-2-microglobulin concen-
tration (P = 0.04), while correlation with the percentage of 
clonal plasma cells in the bone marrow was not as strong 
(P = 0.08). Monoclonal IgAκ or IgAλ isotype concentrations 
higher than normal upper limit (for IgAκ above 2.82 g/L 
and for IgAλ above 1.98 g/L) correlated with serum beta-
2-microglobulin concentration >3.5 mg/L (P = 0.050) and 
abnormal serum FLC ratio (P = 0.005).
Disease variables and uninvolved (polyclonal) hLC 
isotype level
Correlations regarding the suppression of the polyclonal 
HLC isotype pair (ie, suppression of IgGλ in a IgGκ myelo-
ma patient), were also assessed. Suppression was defined 
as an istoype pair value below normal range. In the entire 
group, there were significant correlations between isotype 
pair suppression and abnormal serum FLC ratio (P < 0.001), 
as well as hemoglobin concentration <100 g/L (P = 0.005). 
The same was found when looking at IgG group alone (ab-
normal serum FLC ratio, P < 0.001 and hemoglobin <100 
g/L, P < 0.001), while in the IgA group there were no signifi-
cant correlations between the suppressed polyclonal iso-
type and other tumor markers, possibly due to the small 
number of patients.
hLC measurements and overall survival
The aim of this study was to determine not only the abil-
ity of the new assay to detect monoclonal protein, ie, re-
sidual disease but also the clinical relevance of HLC assay 
measurement in multiple myeloma patients regardless 
of the type of treatment and time elapsed from the last 
course of therapy. For this purpose, Kaplan-Meier analysis 
was performed for OS of patients from the date of enrol-
ment onwards. Patients were stratified according to HLC 
ratio values, and OS was significantly shorter in patients 
with abnormal HLC ratio value (median OS not reached, 
P < 0.001) (Figure 1A). When patients were stratified ac-
cording to monoclonal isotype concentrations, OS was 
significantly shorter in patients with values above nor-
mal range (median 31.7 months vs median not reached, 
P = 0.002) (Figure 1B).
Interestingly, when patients were stratified according to 
the presence or absence of suppression of the uninvolved 
polyclonal HLC isotype pair, those with isotype suppres-
taBLe 2. Results of heavy/light chain (hLC) and free light chain (FLC) assays in multiple myeloma patients in different disease stages
Number of patients with
Results
complete 
response
(N = 23)
very good 
partial response
(N = 34)
partial 
response 
(N = 10)
stable 
disease 
(N = 10)
FLC κ/λ ratio* and HLC Ig´κ/Ig´λ ratio both normal 14 12 0 0
FLC κ/λ ratio and HLC Ig´κ/Ig´λ ratio both abnormal 1 12 10 6
FLC κ/λ ratio abnormal and HLC Ig´κ/Ig´λ ratio normal 4 2 0 1
FLC κ/λ ratio normal and HLC Ig´κ/Ig´λ ratio abnormal 4 8 0 3
*free κ/λ light chain ratio.
†heavy/light Ig’κ/Ig’λ chain ratio.
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sion also had significantly shorter OS (median 31 months 
vs median not reached, P = 0.021, Figure 2).
The clinical relevance of the HLC assay was even more evi-
dent when Kaplan-Meier analysis was performed in pa-
tients who achieved very good partial responses (defined 
as negative SPE and positive IFE) and complete response 
(both SPE and IFE negative). When this subgroup of pa-
tients was stratified according to HLC ratio value, OS was 
significantly shorter in patients with abnormal HLC ratio 
values than in very good partial responses/complete re-
sponse patients with normal HLC ratio (median 27.2 month 
vs median not reached, P = 0.033) (Figure 3).
Prognostic significance of hLC measurements
In order to assess the prognostic significance of the new 
assay, Cox multivariate regression analysis was performed 
for the entire study population and for the group of pa-
tients who achieved very good partial response or bet-
ter. An abnormal HLC ratio as well as high beta-2-micro-
globulin (>3.5 mg/L) concentration were independent 
predictors of OS for the entire cohort (risk ratio [RR] 4.7, 
confidence interval [CI] 0.96-23.47, P = 0.050; RR 4.9, CI 1.59-
15.34, P = 0.005, respectively) (Table 3). When assessing the 
patients with very good partial response or better, the sig-
nificance of abnormal HLC ratio was not as strong as for the 
entire group (RR 3.18, CI 0.84-12.04, P = 0.087).
DISCuSSIoN
Detection of monoclonal immunoglobulin
Using HLC assay, we successfully detected isotype and 
quantified monoclonal Ig in all multiple myeloma patients. 
HLC assay had greater sensitivity for monoclonal disease 
detection than total Ig result. It revealed an abnormal HLC 
ratio in almost half of the patients with total Ig levels within 
FIGuRe 1. overall survival in study population. (A) Patients stratified according to heavy/light chain ratio. those with an abnormal 
value had significantly shorter overall survival (dotted line) than those with normal values (full line, P = 0.0019); median survival 
was not reached in either group. (B) Patients stratified according to monoclonal isotype absolute values. Median survival was 31.7 
months in patients with monoclonal isotype values above normal (dotted line) and was not reached in patients with monoclonal 
isotype values with normal range (full line, P = 0.002).
taBLe 3. Multivariate analysis showed abnormal heavy/light chain ratio to be an independent risk factor for overall survival
Risk factor Relative risk 95% confidence interval P
β2-microglobulin >3.5 mg/L 4.94 1.59-15.34 0.005
Abnormal heavy/light chain ratio* 4.74 0.96-23.47 0.050
Abnormal free light chain ratio 3.29 0.93-11.69 0.064
Serum albumin <35 g/L 2.18 0.67-7.06 0.191
International staging system (stage III) 0.71 0.13-3.90 0.699
*Variables in bold denote statistically significant results (P ≤ 0.05).
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normal range, signifying the presence of monoclonal pro-
tein. Moreover, an abnormal HLC ratio was found in almost 
20% of complete response patients, thus detecting the 
presence of residual disease when other laboratory tech-
niques could not detect it. In support of this, 2 of the 5 
patients in complete response but with an abnormal HLC 
ratio suffered relapse during the follow up period. Similar 
observations of abnormal HLC ratios in patients in com-
plete response have been reported previously (18,23).
The HLC and serum FLC assays provided differing but 
complementary information. This was most apparent in 
patients in complete response: 4 patients had abnormal 
serum FLC ratio and normal HLC ratio, whereas 4 patients 
had the opposite results. Knowing the metabolism of FLC 
and intact Igs, one would expect that the normalization of 
the FLC ratio will precede or occur simultaneously with the 
normalization of HLC ratio. However, our data showed that 
normal HLC ratio values did not necessarily mean normal 
FLC ratio values or vice versa. Similar observations were re-
ported previously (18) and are consistent with the two as-
says providing information on two independent markers of 
myeloma activity – the intact Igs and the FLC (24,25). These 
data suggest that both assays are required for the optimal 
follow-up of multiple myeloma patients. In support of 
this, when response of myeloma patients to treatment 
was assessed, it was shown that in patients achiev-
ing complete response or better, patients with abnormal 
both HLC and FLC ratio had a significantly shorter 2-year 
progression free survival (PFS) than those with either nor-
mal HLC or FLC ratio (26).
Significance of the uninvolved hLC isotype pair 
suppression
Our results showing a strong association of suppression of 
the uninvolved HLC isotype pair with both markers of tu-
mor burden (ie, FLC and hemoglobin) and shorter OS are 
particularly interesting. An analogous correlation of abnor-
mal HLC ratios with shorter PFS in myeloma patients, par-
ticularly with more extreme HLC ratios, has been observed 
previously (27). Interestingly, this association has been 
shown to be driven primarily and specifically by suppres-
sion of the uninvolved polyclonal HLC isotype pair, while 
suppression of the non-tumor Igs of different isotypes 
showed no significant correlation with PFS. Similarly, HLC 
pair suppression has been shown to be an additional inde-
pendent risk factor for progression to malignancy in MGUS 
patients alongside serum monoclonal protein size, heavy 
chain isotype, and an abnormal serum FLC ratio (20). The 
reason for the association of the outcome specifically with 
HLC pair-suppression in myeloma and MGUS remains un-
explained. However, several studies in MGUS patients have 
noted higher levels of HLC pair suppression in IgG patients 
FIGuRe 2. overall survival in patients stratified according to 
polyclonal heavy/light chain (hLC) isotype pair suppression. 
Median overall survival was 31 months in patients showing 
suppressed polyclonal hLC isotypes (dotted line) and was not 
reached in patients without suppression (full line, P = 0.021).
FIGuRe 3. overall survival in patients who achieved very good 
partial response/complete response stratified according to 
heavy/light chain ratio. Patients with an abnormal value had 
significantly shorter overall survival than those with normal 
values; median survival was 27.2 months (dotted line) vs not 
reached (full line, P = 0.002).
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compared to IgA and IgM patients (20,28). An explanation 
for this is that due to relatively higher levels of background 
polyclonal IgG, which may help to prevent invasion of clon-
al plasma cells (29), suppression of normal IgG plasma cells 
may be a requirement for progression in IgG MGUS. Con-
versely, suppression of normal plasma cells may be less of 
a requirement for IgA MGUS progression and may help to 
explain the higher risk of progression shown by IgA MGUS 
patients (28). Interestingly, in multiple myeloma patients, 
we observed similar results of more frequent HLC pair sup-
pression in IgG myeloma, with 35/66 (53%) IgG patients 
showing HLC pair suppression compared to 7/24 (29%) IgA 
patients, although the relative number of IgA patients was 
much lower. As multiple myeloma has been shown to be 
preceded consistently by MGUS (30,31), our data suggests 
that this possible differential requirement for isotype-spe-
cific pair suppression between IgG and IgA MGUS is main-
tained upon progression to multiple myeloma. Therefore, 
HLC pair suppression may be a useful marker of malignant 
disease, suggesting that it is useful to monitor the response 
of multiple myeloma patients to treatment.
hLC measurement values and impact on patients’ 
outcome
Despite the fact that the data in this study were obtained 
from a heterogeneous group of multiple myeloma pa-
tients, we found a strong correlation between an abnor-
mal HLC ratio and other markers of tumor burden (the per-
centage of clonal plasma cells in the bone marrow and an 
abnormal serum FLC ratio). Given the statistical strength 
of the correlation, one might expect this to impact the 
patient outcome. Indeed, patients with abnormal level of 
monoclonal HLC isotype or abnormal HLC ratio had signifi-
cantly shorter OS than patients with normal monoclonal 
HLC isotype level or HLC ratio. In the group of patients who 
achieved very good partial response or better, HLC ratio 
value maintained its impact on patients’ outcome while 
monoclonal HLC isotype concentrations above normal 
range did not.
Prognostic significance of the hLC measurements
In order to further assess the clinical relevance of HLC assay 
in the management of previously treated multiple myelo-
ma patients, we additionally performed multivariate Cox 
regression analysis for the entire group as well as for pa-
tients in very good partial response or better. The analysis 
for the entire cohort confirmed the prognostic relevance 
of the HLC ratio along with high β2-microglobulin values. 
Interestingly, the serum FLC ratio, which has been reported 
as predictive of outcome in several previous studies (32-
35), was not significantly associated with OS in our study, 
most likely due to the fact that we did not include light 
chain multiple myeloma patients. The prognostic utility 
of HLC ratios in multiple myeloma using clinical presenta-
tion samples of untreated patients or patients recruited to 
clinical trials where all individuals received the same che-
motherapeutic treatment followed by autologous stem 
cell transplantation (ASCT) treatment has recently been 
shown (18,27). However, in our study, patients were unse-
lected and so were at different clinical stages of disease, 
received different chemotherapeutic regimes, and only a 
proportion had received ASCT treatment. Even in such a 
sample, we were able to evaluate the clinical utility of the 
HLC assay in everyday practice. Therefore, our finding that 
an abnormal HLC ratio, irrespective of disease stage and 
treatment regimen, is predictive of a poorer outcome in 
multiple myeloma is particularly noteworthy.
In conclusion, our results corroborate previous studies and 
show potential clinical utility of the HLC assay. In our study, 
the HLC ratio values correlated well with other prognostic 
tumor burden markers, showed enhanced sensitivity for 
the detection and quantification of monoclonal proteins, 
and affected patient outcome using a cohort of unselect-
ed patients in a daily practice setting. Interestingly, HLC pair 
suppression also correlated well with other tumor markers 
and was prognostic for shorter overall survival. Multivariate 
analysis confirmed an abnormal HLC ratio as an indepen-
dent prognostic factor. Although larger studies using more 
defined groups of patients are required, our data suggest 
a clear role for HLC measurement in monitoring and re-
sponse assessment of multiple myeloma patients with po-
tential role in predicting patients’ outcome.
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